Mesoblast Limited (MSB.AX)
| Previous close | 1.1250 |
| Open | 1.1100 |
| Bid | 1.3050 x 1092600 |
| Ask | 0.8750 x 5097500 |
| Day's range | 1.0850 - 1.1350 |
| 52-week range | 1.0800 - 2.9000 |
| Volume | |
| Avg. volume | 2,310,886 |
| Market cap | 708.996M |
| Beta (5Y monthly) | 2.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2180 |
| Earnings date | 24 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.92 |
- GlobeNewswire
Mesoblast to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this week. The three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, will take place between January 25-27th, focusing on 33 companies. Mesoblast will feature on Day one - Busines
- GlobeNewswire
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech ShowcaseNEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced 36-month follow-up results from the 404-patient Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD). Mesoblast Chie
- GlobeNewswire
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC) items identified in the complete response letter (CRL) for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in childrenOTAT indicated that Mesoblast’s approach to address the outstanding CMC items is reasonableOTAT indicated that the in vitro immunomodulator
